Thank you for visiting, don't forget to subscribe by following here if you enjoy our content. We use follow.it to give you maximum control over your news.
In a groundbreaking announcement at the World Economic Forum in Davos, Sir Demis Hassabis revealed that Isomorphic Labs, the Alphabet-owned drug discovery startup, will commence trials of its first AI-designed drug by year-end.
The Nobel Prize-winning chief executive outlined ambitious plans to revolutionise drug development through artificial intelligence, potentially reducing the traditional five to ten-year discovery timeline by a factor of ten. The company’s focus spans major therapeutic areas including oncology, cardiovascular disease, and neurodegeneration.
Isomorphic Labs, which emerged from Google’s AI research division in 2021, has already secured partnerships with pharmaceutical giants Eli Lilly and Novartis. These collaborations aim to streamline the costly drug development process, marking a significant shift in how new medicines are discovered.
Beyond pharmaceutical innovations, Hassabis shared insights about Google’s AI developments, including Project Astra, a consumer-focused AI assistant scheduled for release later this year. His vision extends to a near future where billions of AI agents conduct automated negotiations across a reimagined internet landscape.
The DeepMind chief also addressed concerns about artificial general intelligence (AGI), estimating its arrival within five to ten years. He emphasised the need for careful stewardship of AI development, acknowledging that while the technology cannot be contained, its implementation must prioritise safety and ethical considerations.
The convergence of AI and healthcare represents a watershed moment in medical science, with Isomorphic Labs positioning itself at the forefront of this technological revolution. As these trials commence, the healthcare sector watches closely to see if AI can deliver on its promise to transform drug discovery.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.